Silence Therapeutics (SLN) Free Cash Flow (2024 - 2026)

Silence Therapeutics has disclosed Free Cash Flow across 3 years of filings, most recently posting -$15.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$15.6 million, down 26.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$65.6 million (up 7.61% YoY), and the FY2025 annual result was -$62.3 million, up 8.14% from the prior year.
• Free Cash Flow came in at -$15.6 million for Q1 2026 at Silence Therapeutics, up from -$17.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$5.5 million in Q2 2024 to a low of -$27.5 million in Q4 2024.
• The 3-year median for Free Cash Flow is -$15.6 million (2026), against an average of -$16.2 million.
• Peak annual rise in Free Cash Flow reached 57.5% in 2025, while the deepest fall reached 297.38% in 2025.
• Silence Therapeutics' Free Cash Flow stood at -$27.5 million in 2024, then surged by 37.29% to -$17.3 million in 2025, then climbed by 9.68% to -$15.6 million in 2026.
• The last three Free Cash Flow figures came in at -$15.6 million (Q1 2026), -$17.3 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.